Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report
Mesenchymal-epithelial transition factor (MET) gene mutation is a large class of mutations commonly seen in non-small cell lung cancer (NSCLC). MET mutation includes subtypes such as MET exon 14 skipping mutation (METex14m) and MET amplification (METamp). For advanced NSCLC with METex14m, Savolitini...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2024-11-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.36 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544089535774720 |
|---|---|
| author | Meng LU Ran ZHANG Baiwei LI Haidi XU Yongkuan GUO Jian YOU Bingsheng SUN |
| author_facet | Meng LU Ran ZHANG Baiwei LI Haidi XU Yongkuan GUO Jian YOU Bingsheng SUN |
| author_sort | Meng LU |
| collection | DOAJ |
| description | Mesenchymal-epithelial transition factor (MET) gene mutation is a large class of mutations commonly seen in non-small cell lung cancer (NSCLC). MET mutation includes subtypes such as MET exon 14 skipping mutation (METex14m) and MET amplification (METamp). For advanced NSCLC with METex14m, Savolitinib has a high sensitivity as a member of tyrosine kinase inhibitors (TKIs). METamp is a relatively rare genetic mutation type which can serve as a driver gene to mediate primary and later acquired drug resistance of epidermal growth factor receptor (EGFR)-TKIs. For advanced NSCLC with secondary METamp, EGFR-TKIs combined with MET-TKIs are usually used in clinical treatment, while the optimal treatment strategy for advanced NSCLC with primary METamp has not yet been determined. For locally advanced NSCLC patients with positive driver gene mutations such as EGFR, anaplastic lymphoma kinase (ALK) fusion and METex14m, there have been relevant cases reported that neoadjuvant targeted therapy could achieve a good prognosis, but there have been no cases of neoadjuvant targeted therapy for locally advanced NSCLC patients with METamp. This report describes a case of a locally advanced NSCLC patient with dual driver gene mutations (EGFR L858R combined with primary METamp), the tumor did not shrink after 1 month of Gefitinib monotherapy, but significantly subsided after 4 months of Savolitinib monotherapy. After radical surgery, the pathological results proved pathological complete response (pCR) of the tumor, and the patient had a good response to postoperative continual Savolitinib treatment, with no recurrence nor metastasis observed to date. This case reports the feasibility and effectiveness of neoadjuvant targeted therapy for locally advanced NSCLC with primary METamp, aiming to provide effective reference for perioperative treatment of locally advanced NSCLC with primary METamp. |
| format | Article |
| id | doaj-art-b1d45c91b6c9480cb56439d2f80c06f1 |
| institution | Kabale University |
| issn | 1009-3419 1999-6187 |
| language | zho |
| publishDate | 2024-11-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj-art-b1d45c91b6c9480cb56439d2f80c06f12025-01-13T02:46:02ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872024-11-01271187387710.3779/j.issn.1009-3419.2024.102.36Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case ReportMeng LU0Ran ZHANG1Baiwei LI2Haidi XU3Yongkuan GUO4Jian YOU5Bingsheng SUN6Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300000, ChinaDepartment of Thoracic Oncology, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300000, ChinaDepartment of Thoracic Oncology, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300000, ChinaDepartment of Thoracic Oncology, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300000, ChinaDepartment of Thoracic Oncology, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300000, ChinaDepartment of Pulmonary Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300000, ChinaDepartment of Pulmonary Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300000, ChinaMesenchymal-epithelial transition factor (MET) gene mutation is a large class of mutations commonly seen in non-small cell lung cancer (NSCLC). MET mutation includes subtypes such as MET exon 14 skipping mutation (METex14m) and MET amplification (METamp). For advanced NSCLC with METex14m, Savolitinib has a high sensitivity as a member of tyrosine kinase inhibitors (TKIs). METamp is a relatively rare genetic mutation type which can serve as a driver gene to mediate primary and later acquired drug resistance of epidermal growth factor receptor (EGFR)-TKIs. For advanced NSCLC with secondary METamp, EGFR-TKIs combined with MET-TKIs are usually used in clinical treatment, while the optimal treatment strategy for advanced NSCLC with primary METamp has not yet been determined. For locally advanced NSCLC patients with positive driver gene mutations such as EGFR, anaplastic lymphoma kinase (ALK) fusion and METex14m, there have been relevant cases reported that neoadjuvant targeted therapy could achieve a good prognosis, but there have been no cases of neoadjuvant targeted therapy for locally advanced NSCLC patients with METamp. This report describes a case of a locally advanced NSCLC patient with dual driver gene mutations (EGFR L858R combined with primary METamp), the tumor did not shrink after 1 month of Gefitinib monotherapy, but significantly subsided after 4 months of Savolitinib monotherapy. After radical surgery, the pathological results proved pathological complete response (pCR) of the tumor, and the patient had a good response to postoperative continual Savolitinib treatment, with no recurrence nor metastasis observed to date. This case reports the feasibility and effectiveness of neoadjuvant targeted therapy for locally advanced NSCLC with primary METamp, aiming to provide effective reference for perioperative treatment of locally advanced NSCLC with primary METamp.http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.36lung neoplasmsneoadjuvant targeted therapymet amplificationsavolitinibpathological complete response |
| spellingShingle | Meng LU Ran ZHANG Baiwei LI Haidi XU Yongkuan GUO Jian YOU Bingsheng SUN Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report Chinese Journal of Lung Cancer lung neoplasms neoadjuvant targeted therapy met amplification savolitinib pathological complete response |
| title | Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report |
| title_full | Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report |
| title_fullStr | Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report |
| title_full_unstemmed | Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report |
| title_short | Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report |
| title_sort | savolitinib induced pathological complete response in non small cell lung cancer with met amplification a case report |
| topic | lung neoplasms neoadjuvant targeted therapy met amplification savolitinib pathological complete response |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.36 |
| work_keys_str_mv | AT menglu savolitinibinducedpathologicalcompleteresponseinnonsmallcelllungcancerwithmetamplificationacasereport AT ranzhang savolitinibinducedpathologicalcompleteresponseinnonsmallcelllungcancerwithmetamplificationacasereport AT baiweili savolitinibinducedpathologicalcompleteresponseinnonsmallcelllungcancerwithmetamplificationacasereport AT haidixu savolitinibinducedpathologicalcompleteresponseinnonsmallcelllungcancerwithmetamplificationacasereport AT yongkuanguo savolitinibinducedpathologicalcompleteresponseinnonsmallcelllungcancerwithmetamplificationacasereport AT jianyou savolitinibinducedpathologicalcompleteresponseinnonsmallcelllungcancerwithmetamplificationacasereport AT bingshengsun savolitinibinducedpathologicalcompleteresponseinnonsmallcelllungcancerwithmetamplificationacasereport |